Daily Brief Archive: July 22, 2026 — U.S. & Hong Kong Stock Analysis

Free preview

U.S. Markets

  • Nasdaq +1.29%, snapping a 3-day slide; memory led — MU +12%, SNDK +14%
  • Morgan Stanley: memory shortage shows 'no sign of easing,' Q3 prices +25% minimum
  • Gold $4,082, WTI $85, 10Y at 4.63% — the stagflation mix stays on the table
  • Day 9 of US-Iran strikes; Tehran floats talks, oil spikes then fades
  • FOMC meets next week (blackout now); nine officials lean toward a hike this year

Hong Kong

  • HSI flat at 25,132, HSTECH +1.32% — AI hardware counterattacked while oil and coal dragged
  • Southbound flows swung to a net HK$7.17B buy, fully reversing last week's selling
  • A-shares V-reversed with the STAR 50 up 10.73% — AI remains the cross-market consensus
  • Gold above $4,000 lifted the miners in unison — Zhaojin +10.1%, Zijin +4.6%
  • Zhipu roared back +36.9% on the compiler-team buy and a 1GW domestic-chip datacenter

Today's Watchlist

  • Tonight after close: Alphabet, Tesla, IBM and AT&T — the AI-capex referendum
  • Tesla options imply ±6%, the biggest earnings bet in a year — we watch from the rail
  • APLD short covered: the 7/27 print collides with 27% short interest
  • SNPS watches the 7/27 Kimi K3 technical report — the EDA moat's proof-or-disproof moment
  • Thursday: Intel, ServiceNow and the ECB; Friday: global flash PMIs
  • The Section 122 global 10% tariff expires Friday with no defined path forward

Deep Dives (1 names)

Neutral
Score7/10Day -11.0% on 7x volumeQ2 results Beat on revenue & EPSFY core growth guide Cut 3-6% → 3-4%RSI(14) 37.9

Technicals — The -11% close at $179.01 sliced straight through the 50-day ($183.3), sits 12.4% under the 200-day ($204.3), and RSI 37.9 isn't even oversold yet. Distribution at 7.18x volume takes time to absorb; support waits at $170 and the $160.93 52-week low, while any bounce first faces the $183-195 gap-fill zone

Fundamentals — Q2 itself was clean: revenue $6.27B (+5.5%, a beat), adjusted EPS $1.94 (+8%), and full-year EPS guidance actually raised to $8.45-8.60. The damage is all top-line — full-year core growth cut to 3-4%, Q3 at just 2-3%, bioprocessing downgraded from high to mid single digits. Management insists bioprocessing orders grew mid-teens and demand is delayed, not destroyed

News — The 7/21 pre-market report triggered the gap: the ugliest line was $100M+ of bioprocessing revenue slipping to 2027 on customer project timing, with the stock down as much as 14.6% intraday. Post-earnings target revisions haven't printed yet — consensus still reflects pre-crash ~$235 and 88% Buy ratings, and the coming wave of cuts is itself a second source of pressure

Short-term · 2-4 weeks
Neutral Sidelines

Guidance cut, 7x-volume distribution and an unlanded wave of target cuts — three pressures argue against catching the first knife. If $165-172 (above the 52-week low) holds on shrinking volume, the gap-fill toward $195 becomes playable with a stop under the low

Entry Scale in on stabilization at $165-172Stop $159Target $195
Long-term · months+
Neutral

Bioprocessing orders up mid-teens say demand is on the mend and the 61%-gross-margin compounder DNA is intact; but a recovery deferred to 2027 needs two or three quarters of proof, leaving the multiple catalyst-poor meanwhile

  • Bioprocessing recovery slipping again
  • A second leg down as post-earnings downgrades land
  • Soft healthcare capex bleeding into diagnostics
Community Voices
  • WSB · A rare medtech name on the trending list — retail sees -11% and yells 'dip,' but sell orders at 7x volume never lack confident knife-catchers on the other sideOriginal ↗
Institutional Views
  • 华尔街共识 · 29 analysts average $240 (a pre-crash number) at a 1.22 Strong Buy — but post-earnings cuts haven't landed yet, so the headline +34% upside will shrink
  • Evercore ISI · Outperform maintained 7/6, target $232 → $230 (pre-earnings)Source ↗
  • Piper Sandler · Initiated at just Neutral with a $200 target on 6/11 — the most cautious pre-earnings voice now looks the most realisticSource ↗

Rapid Scan (12 names)

TickerCloseChangeScoreDirectionOne-line take
MMM logoMMMUS$170.76+7.32%6NeutralA +7.3% surge on 3.8x volume onto the hot list at RSI 68 — industrials' earnings-week standard-bearer, but chasing a one-day spike has poor odds
SPOT logoSPOTUS$493.23+0.18%6NeutralConsolidating on 2x volume, 34% off the high; the price-hike-plus-audiobooks story lives — wait for earnings to confirm subscriber momentum
TMO logoTMOUS$523.46-0.53%6NeutralPeer Danaher's blowup sours medtech sentiment while its own +13.4% month shows resilience — sidelines into earnings
TXN logoTXNUS$291.3+2.55%6NeutralThe analog bellwether rode the semi rally +2.5% with earnings due this week — no front-running before the cycle inflection confirms
BA logoBAUS$204.8-2.23%5NeutralWeak against the tape at -2.2%, RSI 35, with 2.3x volume betraying rising disagreement — let delivery data speak
HL logoHLUS$15.29+7.00%5NeutralSilver's 4-5% spike past $59 launched the miner +7% — fierce commodity beta, but 55% off the high, chasing means buying volatility
MOH logoMOHUS$226.54-1.38%5NeutralA -1.4% close on 9.6x monster volume as managed-care bulls and bears collide into earnings — stay out until the dust settles
NOC logoNOCUS$512.29-2.23%5NeutralA defense name down 2.2% on day nine of the US-Iran conflict — the classic good-news-exhausted pattern, sidelines
PATH logoPATHUS$12.04-0.99%5NeutralRepairing with an +18% month at RSI 62 as the AI-agent narrative grants a second life — still 7% under the 200-day, no trend reversal yet
PSA logoPSAUS$309.75-1.83%5NeutralDown 1.8% on 3.8x volume — the storage REIT feels the 10-year at 4.63%, a headwind; sidelines
SCHW logoSCHWUS$99.96-2.52%5NeutralGiving back post-earnings gains at -2.5%; retail trading heat is the backdrop — revisit near the 50-day
T logoTUS$22.26+1.41%5NeutralOne of tonight's four big reports with 2x volume front-running; the valuation floor at $22.26 is thick, the catalyst just hasn't landed
Stock Brief 2026-07-22: Daily U.S. & HK Market Analysis Archive · Quant Brief